This capital increase aims to further strengthen ImmuneCare's financial resources and accelerate the research and development of innovative drugs in cardiovascular diseases, such as pulmonary arterial hypertension (PAH), as well as metabolic diseases. This marks the steady implementation of ImmuneOnco's "oncology + non-oncology" dual-engine strategy.

The event aimed to provide a comprehensive overview of the study protocol and unify trial execution standards, laying a solid foundation for the clinical study that is now fully underway.

This milestone is expected to provide a novel treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.

Previously, the study met its pre-specified interim analysis enrollment target of 132 patients ahead of schedule in March 2026 (with an actual enrollment of 133 patients), and completed the full enrollment of 173 patients in June 2026.

This significant milestone marks the official commencement of the clinical development of this innovative drug in the field of rare autoimmune diseases, bringing new therapeutic hope to IgG4-RD patients who face substantial unmet medical needs.